Teva Pharmaceutical Industries Ltd. has received the US Food and Drug (FDA) Administration has granted final approval for the company's Abbreviated New Drug Application (ANDA) for Venlafaxine Hydrochloride tablets, 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg. Shipment of this product will begin immediately, a company release said.
Teva's Venlafaxine HCl Tablets are the AB-rated generic equivalent of Wyeth's Effexor tablets, a product indicated for the treatment of major depressive disorder. The brand product has annual sales of approximately $152 million.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 per cent of Teva's sales are in North America and Europe.